Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
Acronym
ConcePTION
Description of the granted funding
ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and lactation.
What do we deliver? ConcePTION aims to create a paradigm shift in how we study medication safety in pregnancy. We will establish (1) a successful, sustainable open-science based EU non-proprietary ecosystem of public and private stakeholders, pregnant women and researchers to generate and disseminate timely and reliable evidence on drugs across maternal, neonatal and long term outcomes of medication exposure in pregnancy and breastfeeding (2) a catalogue with fully characterized data sources for rapid selection of suitable data sources; 3) operational, business, network, information and data governance models, (4) quality assured and tested methodological approaches, analytical tools and data platforms allowing for distributed analyses, (5) procedures and tools for collection of digital data and samples directly from pregnant women, (6) In vitro, in silico and in vivo models for prediction of drug transfer in human milk, (7) a biobank and analytical network for quantification of drug in human milk, (8) best practice documents endorsed by regulators and health authorities and (9) a web-based drug information knowledge bank.
How do we deliver? (1) Experienced leaders, able to manage challenging networks and public-public or public-private partnerships. (2) Defragmentation by connecting all key stakeholders and EU networks in this area. (3) Re-use of data, tools and foreground from prior European commission funded projects. (4) Connecting to leaders of similar initiatives in the USA, Canada, Asia and other parts of the world. (5) Systematic consensus & endorsement building. (6) Quality throughout as a precondition to trust the results and information by all users.
Show moreStarting year
2019
End year
2024
Granted funding
NEARSHORE MACEDONIA LTD SKOPJE (MK)
141 188.25 €
Third party
SHAMIR HEALTH CORPORATION (IL)
70 000 €
Third party
MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (UK)
8 783.75 €
Third party
SYNERGIST SERVICES (BE)
167 311.8 €
Third party
ORCION BV (NL)
94 125.5 €
Participant
BIONOTUS (BE)
355 143.75 €
Participant
STICHTING ENTIS (EUROPEAN NETWORK TERATOLOGY INFORMATION SERVICES) FOUNDATION (NL)
303 262 €
Participant
THE SYNERGIST (BE)
137 421 €
Participant
ELLEGAARD GOTTINGEN MINIPIGS AS (DK)
Participant
THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA (BE)
466 011.25 €
Participant
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL)
Participant
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (UK)
108 218.75 €
Participant
UCB BIOPHARMA SPRL (BE)
Participant
ELEVATE BV (NL)
110 918.75 €
Participant
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN (DE)
Participant
BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE CONSORTIUM(BBMRI-ERIC) (AT)
201 000 €
Participant
TAKEDA PHARMACEUTICALS INTERNATIONAL AG (CH)
Participant
ABBVIE INC (US)
Participant
TTOPSTART BV (NL)
67 130 €
Participant
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA (ES)
89 868.75 €
Participant
COVANCE LABORATORIES LTD (UK)
Participant
BRISTOL-MYERS SQUIBB COMPANY CORP (US)
Participant
Srebrnjak Children's Hospital (HR)
5 720 €
Third party
Eli Lilly and Company Limited (UK)
Participant
EUROPEAN INSTITUTE OF WOMEN'S HEALTH COMPANY LIMITED BY GUARANTEE (IE)
135 160 €
Participant
THE EUROPEAN MEDICINES AGENCY (NL)
85 000 €
Participant
STICHTING LAREB (NL)
848 022.5 €
Participant
PFIZER LIMITED (UK)
Participant
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR)
Participant
JANSSEN PHARMACEUTICA NV (BE)
Participant
UPPSALA LANS LANDSTING (SE)
171 140 €
Participant
HOSPICES CIVILS DE LYON (FR)
39 334 €
Third party
STOCKHOLMS LANS LANDSTING (SE)
119 911.25 €
Participant
MINISTRY OF HEALTH (IL)
26 250 €
Third party
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (UK)
552 695.38 €
Participant
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH)
482 805.75 €
Participant
AGENZIA REGIONALE DI SANITA (IT)
359 110 €
Participant
NOVARTIS PHARMA AG (CH)
Participant
MEDIZINISCHE UNIVERSITAT GRAZ (AT)
60 000 €
Third party
UNIVERSITA DEGLI STUDI DI FERRARA (IT)
275 673.75 €
Participant
UNIVERSITAET LEIPZIG (DE)
25 000 €
Third party
SWANSEA UNIVERSITY (UK)
171 182.75 €
Participant
ST GEORGE'S HOSPITAL MEDICAL SCHOOL (UK)
370 323.75 €
Participant
Masarykova univerzita (CZ)
42 420 €
Third party
UNIVERSITY OF ULSTER (UK)
692 409.75 €
Participant
UNIVERSITY OF KWAZULU-NATAL (ZA)
132 722.13 €
Participant
UNIVERSITY OF KWAZULU-NATAL (ZA)
229 223.75 €
Participant
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR)
912 928.75 €
Participant
THE UNIVERSITY OF MANCHESTER (UK)
355 466.25 €
Participant
ACADEMISCH ZIEKENHUIS GRONINGEN (NL)
260 938.75 €
Participant
UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL)
2 486 436.44 €
Coordinator
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. (UK)
Participant
NOVO NORDISK A/S (DK)
Participant
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE (BE)
94 992.5 €
Participant
UNIVERSITETET I OSLO (NO)
746 665 €
Participant
UNIVERSITETET I OSLO (NO)
806 665 €
Participant
KAROLINSKA INSTITUTET (SE)
68 207.5 €
Participant
CONSIGLIO NAZIONALE DELLE RICERCHE (IT)
143 222.5 €
Participant
UPPSALA UNIVERSITET (SE)
894 281.25 €
Participant
KATHOLIEKE UNIVERSITEIT LEUVEN (BE)
1 052 746.25 €
Participant
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (NL)
107 321.25 €
Participant
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA (IT)
832 760 €
Participant
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
60 721.25 €
Participant
Amount granted
15 299 991 €
Funder
European Union
Funding instrument
Research and Innovation action
Framework programme
Horizon 2020 Framework Programme
Call
Programme part
Health (5290 Innovative Medicines Initiative 2 (IMI2) (5312 )
Topic
ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now (IMI2-2017-13-09Call ID
H2020-JTI-IMI2-2017-13-two-stage Other information
Funding decision number
821520
Identified topics
health care